Biosimilars could still pack revenue-busting punch, analyst suggests

A typical biosimilar launched in the U.S. will erode about 20% of branded drug sales in the first year following market launch and nearly half of revenues within three years, a June 12 analysis from Leerink analyst Geoffrey Porges suggests.